 Michael Strong
Concepts (411)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium Infections, Nontuberculous | 27 | 2025 | 366 | 5.810 |
Why?
| | Genome, Bacterial | 15 | 2024 | 155 | 3.790 |
Why?
| | Mycobacterium | 11 | 2023 | 116 | 3.500 |
Why?
| | Nontuberculous Mycobacteria | 16 | 2024 | 208 | 3.150 |
Why?
| | Mycobacterium tuberculosis | 19 | 2023 | 334 | 2.640 |
Why?
| | Mycobacterium abscessus | 12 | 2025 | 118 | 2.370 |
Why?
| | Whole Genome Sequencing | 5 | 2025 | 182 | 1.630 |
Why?
| | Mycobacterium Infections | 6 | 2021 | 61 | 1.540 |
Why?
| | Amyotrophic Lateral Sclerosis | 3 | 2021 | 98 | 1.510 |
Why?
| | Neurodegenerative Diseases | 8 | 2025 | 150 | 1.450 |
Why?
| | Cystic Fibrosis | 13 | 2025 | 1158 | 1.300 |
Why?
| | Tuberculosis | 8 | 2023 | 289 | 1.250 |
Why?
| | Frontotemporal Dementia | 4 | 2023 | 57 | 1.140 |
Why?
| | Genomics | 7 | 2021 | 833 | 1.110 |
Why?
| | Phylogeny | 14 | 2021 | 1015 | 1.010 |
Why?
| | Genotype | 6 | 2024 | 1833 | 0.950 |
Why?
| | Antitubercular Agents | 8 | 2023 | 215 | 0.910 |
Why?
| | Genome, Viral | 3 | 2021 | 218 | 0.850 |
Why?
| | Bacteriophages | 3 | 2022 | 111 | 0.850 |
Why?
| | Computational Biology | 9 | 2018 | 680 | 0.830 |
Why?
| | Lung Diseases | 3 | 2022 | 787 | 0.830 |
Why?
| | Methylobacterium | 1 | 2023 | 3 | 0.810 |
Why?
| | Sequence Analysis, DNA | 8 | 2022 | 824 | 0.780 |
Why?
| | High-Throughput Nucleotide Sequencing | 6 | 2022 | 549 | 0.770 |
Why?
| | Protein Domains | 1 | 2024 | 313 | 0.750 |
Why?
| | Herpesvirus 4, Human | 5 | 2016 | 176 | 0.740 |
Why?
| | Genetic Variation | 8 | 2021 | 982 | 0.720 |
Why?
| | Drug Resistance, Bacterial | 8 | 2024 | 196 | 0.720 |
Why?
| | Multifunctional Enzymes | 1 | 2021 | 2 | 0.680 |
Why?
| | Viral Nonstructural Proteins | 1 | 2021 | 67 | 0.680 |
Why?
| | Lipodystrophy | 1 | 2021 | 14 | 0.680 |
Why?
| | RNA-Binding Protein FUS | 1 | 2021 | 15 | 0.670 |
Why?
| | RNA Helicases | 1 | 2021 | 31 | 0.660 |
Why?
| | Lamin Type A | 1 | 2021 | 51 | 0.660 |
Why?
| | Databases, Genetic | 3 | 2018 | 248 | 0.660 |
Why?
| | Lysogeny | 1 | 2020 | 6 | 0.660 |
Why?
| | Prophages | 1 | 2020 | 9 | 0.650 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 130 | 0.650 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2020 | 636 | 0.640 |
Why?
| | DNA-Binding Proteins | 5 | 2024 | 1497 | 0.620 |
Why?
| | Mutation, Missense | 2 | 2021 | 340 | 0.610 |
Why?
| | Plasmids | 1 | 2020 | 379 | 0.610 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1983 | 0.600 |
Why?
| | DNA Helicases | 1 | 2021 | 143 | 0.600 |
Why?
| | Bacterial Proteins | 10 | 2016 | 954 | 0.600 |
Why?
| | Viruses | 1 | 2021 | 165 | 0.580 |
Why?
| | Cross Infection | 4 | 2025 | 262 | 0.580 |
Why?
| | Hawaii | 5 | 2023 | 46 | 0.570 |
Why?
| | Humans | 79 | 2025 | 144261 | 0.570 |
Why?
| | Mutation | 3 | 2021 | 4085 | 0.550 |
Why?
| | Soil Microbiology | 2 | 2020 | 218 | 0.550 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2021 | 2143 | 0.550 |
Why?
| | Equipment Contamination | 2 | 2016 | 71 | 0.540 |
Why?
| | DNA, Bacterial | 5 | 2021 | 342 | 0.540 |
Why?
| | Microbial Sensitivity Tests | 5 | 2024 | 370 | 0.530 |
Why?
| | Tissue Adhesives | 1 | 2017 | 22 | 0.510 |
Why?
| | Dura Mater | 1 | 2017 | 35 | 0.500 |
Why?
| | Respiratory System | 1 | 2017 | 149 | 0.480 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2017 | 70 | 0.480 |
Why?
| | Research Personnel | 1 | 2018 | 183 | 0.470 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2021 | 341 | 0.470 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 316 | 0.460 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2016 | 81 | 0.460 |
Why?
| | Viral Matrix Proteins | 1 | 2015 | 29 | 0.460 |
Why?
| | Frontotemporal Lobar Degeneration | 1 | 2015 | 19 | 0.460 |
Why?
| | Cardiac Surgical Procedures | 2 | 2019 | 609 | 0.450 |
Why?
| | Software | 5 | 2022 | 690 | 0.440 |
Why?
| | Databases, Nucleic Acid | 1 | 2014 | 39 | 0.430 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2015 | 118 | 0.430 |
Why?
| | Disease Outbreaks | 4 | 2025 | 422 | 0.430 |
Why?
| | Cerebrovascular Disorders | 2 | 2025 | 103 | 0.420 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2015 | 101 | 0.410 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2015 | 202 | 0.410 |
Why?
| | Stomach Neoplasms | 1 | 2015 | 126 | 0.400 |
Why?
| | Skin Diseases, Bacterial | 1 | 2013 | 22 | 0.400 |
Why?
| | Systems Biology | 1 | 2014 | 72 | 0.390 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2359 | 0.390 |
Why?
| | Microbiota | 1 | 2021 | 781 | 0.390 |
Why?
| | Tuberculosis, Pulmonary | 4 | 2016 | 131 | 0.380 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 557 | 0.370 |
Why?
| | Respiratory Tract Diseases | 1 | 2014 | 175 | 0.370 |
Why?
| | tau Proteins | 5 | 2025 | 114 | 0.360 |
Why?
| | Ontario | 6 | 2025 | 96 | 0.350 |
Why?
| | Cognition Disorders | 1 | 2015 | 537 | 0.340 |
Why?
| | Molybdenum | 2 | 2021 | 10 | 0.340 |
Why?
| | Cognitive Dysfunction | 4 | 2025 | 451 | 0.330 |
Why?
| | Amino Acid Substitution | 2 | 2021 | 304 | 0.320 |
Why?
| | Sputum | 6 | 2021 | 308 | 0.320 |
Why?
| | Metagenomics | 2 | 2021 | 181 | 0.310 |
Why?
| | Hydrogels | 1 | 2017 | 697 | 0.310 |
Why?
| | Protein Binding | 4 | 2024 | 2270 | 0.300 |
Why?
| | Alzheimer Disease | 3 | 2023 | 619 | 0.290 |
Why?
| | Physicians | 1 | 2018 | 938 | 0.290 |
Why?
| | Proteins | 3 | 2014 | 1021 | 0.290 |
Why?
| | RNA, Viral | 2 | 2024 | 687 | 0.280 |
Why?
| | Lung | 6 | 2023 | 4108 | 0.280 |
Why?
| | RNA | 2 | 2014 | 939 | 0.270 |
Why?
| | United States | 10 | 2022 | 15876 | 0.260 |
Why?
| | Proteomics | 4 | 2010 | 1191 | 0.260 |
Why?
| | Genes, Bacterial | 4 | 2017 | 166 | 0.250 |
Why?
| | Gene Expression Profiling | 9 | 2023 | 1782 | 0.250 |
Why?
| | Treatment Outcome | 4 | 2025 | 11643 | 0.250 |
Why?
| | Chromosome Mapping | 2 | 2023 | 509 | 0.240 |
Why?
| | Canada | 2 | 2018 | 428 | 0.240 |
Why?
| | Bacterial Typing Techniques | 2 | 2017 | 44 | 0.230 |
Why?
| | Cluster Analysis | 4 | 2014 | 519 | 0.220 |
Why?
| | Tuberculosis, Multidrug-Resistant | 3 | 2016 | 50 | 0.220 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 405 | 0.210 |
Why?
| | Evolution, Molecular | 2 | 2021 | 513 | 0.210 |
Why?
| | Virulence | 3 | 2020 | 278 | 0.210 |
Why?
| | Soil | 3 | 2022 | 214 | 0.210 |
Why?
| | Reference Standards | 1 | 2024 | 177 | 0.210 |
Why?
| | DNA Repeat Expansion | 2 | 2014 | 12 | 0.210 |
Why?
| | Immunity, Innate | 3 | 2021 | 846 | 0.200 |
Why?
| | Gene Expression | 2 | 2021 | 1487 | 0.200 |
Why?
| | Microvessels | 1 | 2025 | 98 | 0.200 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2024 | 104 | 0.200 |
Why?
| | Self Concept | 1 | 2025 | 252 | 0.200 |
Why?
| | Brain | 3 | 2025 | 2930 | 0.200 |
Why?
| | White Matter | 1 | 2025 | 151 | 0.190 |
Why?
| | Multigene Family | 1 | 2003 | 203 | 0.190 |
Why?
| | Data Accuracy | 1 | 2023 | 65 | 0.190 |
Why?
| | Neuropsychological Tests | 3 | 2017 | 1129 | 0.190 |
Why?
| | Scoliosis | 1 | 2025 | 223 | 0.190 |
Why?
| | Gene Expression Regulation, Bacterial | 5 | 2023 | 327 | 0.190 |
Why?
| | Transcriptome | 4 | 2023 | 1044 | 0.190 |
Why?
| | Virus Replication | 2 | 2016 | 529 | 0.180 |
Why?
| | Spinal Fusion | 1 | 2025 | 260 | 0.180 |
Why?
| | Phosphoproteins | 1 | 2024 | 343 | 0.180 |
Why?
| | Protein Conformation, beta-Strand | 1 | 2021 | 19 | 0.180 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2021 | 19 | 0.180 |
Why?
| | Furin | 1 | 2021 | 13 | 0.180 |
Why?
| | Asia | 1 | 2021 | 70 | 0.180 |
Why?
| | Male | 21 | 2025 | 72035 | 0.180 |
Why?
| | Africa | 1 | 2021 | 114 | 0.170 |
Why?
| | Biomedical Research | 2 | 2018 | 709 | 0.170 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 123 | 0.170 |
Why?
| | Epidemiological Monitoring | 1 | 2021 | 69 | 0.170 |
Why?
| | Genome Size | 1 | 2020 | 11 | 0.170 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 86 | 0.170 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 148 | 0.170 |
Why?
| | Transcription, Genetic | 6 | 2023 | 1495 | 0.170 |
Why?
| | Alanine | 1 | 2021 | 171 | 0.160 |
Why?
| | Europe | 1 | 2021 | 412 | 0.160 |
Why?
| | Models, Molecular | 3 | 2016 | 1618 | 0.160 |
Why?
| | HEK293 Cells | 2 | 2021 | 744 | 0.160 |
Why?
| | Structure-Activity Relationship | 2 | 2016 | 567 | 0.160 |
Why?
| | Middle Aged | 14 | 2025 | 35762 | 0.160 |
Why?
| | Bacteriological Techniques | 1 | 2021 | 68 | 0.160 |
Why?
| | Water Pollution | 1 | 2020 | 9 | 0.160 |
Why?
| | Killer Cells, Natural | 2 | 2014 | 467 | 0.160 |
Why?
| | Metagenome | 1 | 2021 | 149 | 0.160 |
Why?
| | Water Quality | 1 | 2020 | 36 | 0.160 |
Why?
| | Antigens, Bacterial | 2 | 2014 | 125 | 0.150 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2020 | 86 | 0.150 |
Why?
| | Bone Neoplasms | 1 | 2022 | 253 | 0.150 |
Why?
| | Membrane Lipids | 1 | 2020 | 83 | 0.150 |
Why?
| | Immune Evasion | 1 | 2020 | 64 | 0.150 |
Why?
| | Bone and Bones | 1 | 2022 | 313 | 0.150 |
Why?
| | Adaptation, Physiological | 3 | 2023 | 569 | 0.150 |
Why?
| | Apolipoproteins E | 1 | 2019 | 93 | 0.150 |
Why?
| | Pneumonia | 2 | 2023 | 630 | 0.150 |
Why?
| | Aged | 11 | 2025 | 25850 | 0.140 |
Why?
| | Protein Conformation | 2 | 2016 | 946 | 0.140 |
Why?
| | Phospholipids | 1 | 2020 | 211 | 0.140 |
Why?
| | Binding Sites | 1 | 2021 | 1327 | 0.140 |
Why?
| | Adult | 14 | 2025 | 40262 | 0.140 |
Why?
| | Female | 17 | 2025 | 77976 | 0.140 |
Why?
| | Databases, Factual | 2 | 2021 | 1484 | 0.140 |
Why?
| | Host-Pathogen Interactions | 3 | 2016 | 371 | 0.140 |
Why?
| | Training Support | 1 | 2018 | 35 | 0.130 |
Why?
| | Mycolic Acids | 1 | 2017 | 7 | 0.130 |
Why?
| | Fomites | 1 | 2017 | 7 | 0.130 |
Why?
| | Base Composition | 1 | 2017 | 82 | 0.130 |
Why?
| | Virus Diseases | 1 | 2020 | 216 | 0.130 |
Why?
| | Oregon | 1 | 2017 | 76 | 0.130 |
Why?
| | Longitudinal Studies | 3 | 2025 | 2926 | 0.130 |
Why?
| | Neurofilament Proteins | 2 | 2025 | 77 | 0.130 |
Why?
| | Valsalva Maneuver | 1 | 2017 | 10 | 0.130 |
Why?
| | Biological Specimen Banks | 1 | 2018 | 101 | 0.130 |
Why?
| | Disease | 1 | 2018 | 98 | 0.130 |
Why?
| | Water Supply | 1 | 2017 | 88 | 0.130 |
Why?
| | Surgical Equipment | 1 | 2016 | 9 | 0.130 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1906 | 0.120 |
Why?
| | Sensation Disorders | 1 | 2017 | 41 | 0.120 |
Why?
| | Brazil | 2 | 2014 | 179 | 0.120 |
Why?
| | DNA Gyrase | 1 | 2016 | 12 | 0.120 |
Why?
| | Gait Disorders, Neurologic | 1 | 2017 | 45 | 0.120 |
Why?
| | Fluoroquinolones | 1 | 2016 | 44 | 0.120 |
Why?
| | Family | 1 | 2021 | 679 | 0.120 |
Why?
| | Web Browser | 1 | 2015 | 14 | 0.120 |
Why?
| | Catalase | 1 | 2016 | 130 | 0.120 |
Why?
| | Guidelines as Topic | 1 | 2018 | 267 | 0.120 |
Why?
| | Gene Ontology | 1 | 2015 | 53 | 0.120 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2015 | 27 | 0.120 |
Why?
| | Language Disorders | 1 | 2015 | 29 | 0.120 |
Why?
| | Career Choice | 1 | 2018 | 236 | 0.120 |
Why?
| | Rifampin | 1 | 2016 | 82 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2021 | 767 | 0.110 |
Why?
| | Social Perception | 1 | 2017 | 107 | 0.110 |
Why?
| | Mouth Mucosa | 1 | 2016 | 88 | 0.110 |
Why?
| | Mentors | 1 | 2018 | 218 | 0.110 |
Why?
| | Molecular Sequence Annotation | 1 | 2015 | 105 | 0.110 |
Why?
| | Housing | 1 | 2016 | 144 | 0.110 |
Why?
| | Bacterial Toxins | 1 | 2016 | 108 | 0.110 |
Why?
| | Octamer Transcription Factors | 1 | 2015 | 3 | 0.110 |
Why?
| | Nuclear Matrix-Associated Proteins | 1 | 2015 | 7 | 0.110 |
Why?
| | Isoniazid | 1 | 2016 | 71 | 0.110 |
Why?
| | Genes, Viral | 1 | 2015 | 90 | 0.110 |
Why?
| | Cohort Studies | 6 | 2025 | 5935 | 0.110 |
Why?
| | Virus Activation | 1 | 2016 | 95 | 0.110 |
Why?
| | Neurosurgical Procedures | 1 | 2017 | 202 | 0.110 |
Why?
| | Tumor Escape | 1 | 2015 | 49 | 0.110 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 558 | 0.110 |
Why?
| | Data Mining | 1 | 2016 | 117 | 0.110 |
Why?
| | Herpesviridae | 1 | 2014 | 22 | 0.110 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2015 | 94 | 0.110 |
Why?
| | Viral Core Proteins | 1 | 2014 | 22 | 0.110 |
Why?
| | Adaptive Immunity | 1 | 2016 | 169 | 0.110 |
Why?
| | Education, Medical | 1 | 2018 | 273 | 0.110 |
Why?
| | Retroviridae | 1 | 2014 | 101 | 0.110 |
Why?
| | Neuroimaging | 1 | 2017 | 289 | 0.110 |
Why?
| | Genetic Linkage | 2 | 2006 | 273 | 0.100 |
Why?
| | Tuberculosis Vaccines | 1 | 2014 | 5 | 0.100 |
Why?
| | Colorado | 5 | 2024 | 4562 | 0.100 |
Why?
| | Biofilms | 1 | 2016 | 278 | 0.100 |
Why?
| | RNA, Untranslated | 1 | 2015 | 123 | 0.100 |
Why?
| | Postural Balance | 1 | 2017 | 240 | 0.100 |
Why?
| | Operon | 2 | 2003 | 69 | 0.100 |
Why?
| | Aged, 80 and over | 6 | 2025 | 8243 | 0.100 |
Why?
| | Language | 1 | 2017 | 321 | 0.100 |
Why?
| | Biomarkers | 3 | 2025 | 4254 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 3 | 2025 | 3857 | 0.100 |
Why?
| | Survival Analysis | 1 | 2017 | 1382 | 0.100 |
Why?
| | Extracellular Vesicles | 1 | 2016 | 170 | 0.100 |
Why?
| | Heterozygote | 1 | 2014 | 315 | 0.100 |
Why?
| | B-Lymphocytes | 2 | 2016 | 876 | 0.100 |
Why?
| | Conserved Sequence | 2 | 2003 | 245 | 0.100 |
Why?
| | Lymphoma | 1 | 2014 | 232 | 0.100 |
Why?
| | Galectins | 1 | 2013 | 27 | 0.100 |
Why?
| | Brain Concussion | 1 | 2021 | 638 | 0.100 |
Why?
| | Hepacivirus | 1 | 2014 | 243 | 0.090 |
Why?
| | Phenotype | 3 | 2016 | 3157 | 0.090 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5813 | 0.090 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2020 | 691 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1487 | 0.090 |
Why?
| | Virulence Factors | 1 | 2014 | 172 | 0.090 |
Why?
| | Genetic Association Studies | 1 | 2014 | 372 | 0.090 |
Why?
| | Epidemics | 1 | 2013 | 98 | 0.090 |
Why?
| | Motor Activity | 1 | 2017 | 720 | 0.090 |
Why?
| | Amyloid beta-Peptides | 2 | 2025 | 240 | 0.090 |
Why?
| | Herpesviridae Infections | 1 | 2013 | 150 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 2134 | 0.090 |
Why?
| | Sequence Analysis, RNA | 1 | 2014 | 442 | 0.090 |
Why?
| | RNA-Binding Proteins | 1 | 2015 | 462 | 0.080 |
Why?
| | Young Adult | 5 | 2025 | 13990 | 0.080 |
Why?
| | DNA, Viral | 1 | 2012 | 358 | 0.080 |
Why?
| | Nerve Tissue Proteins | 1 | 2014 | 592 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5389 | 0.080 |
Why?
| | Base Sequence | 1 | 2013 | 2187 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2021 | 3592 | 0.080 |
Why?
| | Epithelial Cells | 1 | 2016 | 1125 | 0.070 |
Why?
| | MicroRNAs | 1 | 2016 | 700 | 0.070 |
Why?
| | Activities of Daily Living | 2 | 2023 | 440 | 0.070 |
Why?
| | Mice, Inbred C57BL | 4 | 2023 | 5988 | 0.070 |
Why?
| | Time Factors | 2 | 2021 | 7155 | 0.070 |
Why?
| | Species Specificity | 2 | 2020 | 574 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2021 | 433 | 0.070 |
Why?
| | Signal Transduction | 2 | 2016 | 5221 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2917 | 0.060 |
Why?
| | Cell Wall | 2 | 2006 | 61 | 0.060 |
Why?
| | Public Health | 1 | 2012 | 564 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2603 | 0.060 |
Why?
| | Mice | 5 | 2023 | 18329 | 0.060 |
Why?
| | Treatment Failure | 2 | 2021 | 363 | 0.060 |
Why?
| | Solubility | 1 | 2006 | 242 | 0.060 |
Why?
| | Uganda | 2 | 2016 | 91 | 0.060 |
Why?
| | Cloning, Molecular | 1 | 2006 | 539 | 0.060 |
Why?
| | Disease Models, Animal | 3 | 2023 | 4556 | 0.060 |
Why?
| | Diffusion Tensor Imaging | 1 | 2025 | 73 | 0.050 |
Why?
| | Crystallography, X-Ray | 1 | 2006 | 492 | 0.050 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 123 | 0.050 |
Why?
| | Atrophy | 1 | 2025 | 200 | 0.050 |
Why?
| | Protein Kinases | 2 | 2016 | 315 | 0.050 |
Why?
| | Arizona | 1 | 2024 | 81 | 0.050 |
Why?
| | C9orf72 Protein | 2 | 2014 | 13 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 758 | 0.050 |
Why?
| | Galactans | 1 | 2003 | 4 | 0.050 |
Why?
| | Glutamate-Ammonia Ligase | 1 | 2003 | 9 | 0.050 |
Why?
| | Mexico | 1 | 2024 | 233 | 0.050 |
Why?
| | Iron | 2 | 2022 | 359 | 0.050 |
Why?
| | Genome | 1 | 2006 | 306 | 0.050 |
Why?
| | Risk Factors | 3 | 2025 | 10699 | 0.050 |
Why?
| | Dust | 1 | 2023 | 102 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2014 | 223 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2018 | 3403 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2024 | 191 | 0.050 |
Why?
| | Animals | 6 | 2023 | 38030 | 0.050 |
Why?
| | Proteome | 2 | 2006 | 514 | 0.050 |
Why?
| | Mycobacterium avium Complex | 1 | 2023 | 88 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2006 | 736 | 0.040 |
Why?
| | Oxides | 1 | 2022 | 51 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2025 | 17009 | 0.040 |
Why?
| | Clarithromycin | 1 | 2021 | 25 | 0.040 |
Why?
| | Armadillos | 1 | 2021 | 2 | 0.040 |
Why?
| | Mycobacterium leprae | 1 | 2021 | 10 | 0.040 |
Why?
| | Macrolides | 1 | 2021 | 69 | 0.040 |
Why?
| | HIV Infections | 1 | 2016 | 3079 | 0.040 |
Why?
| | Clone Cells | 1 | 2021 | 266 | 0.040 |
Why?
| | Cell Membrane | 2 | 2020 | 706 | 0.040 |
Why?
| | Smokers | 1 | 2021 | 137 | 0.040 |
Why?
| | Benchmarking | 1 | 2022 | 188 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2023 | 1044 | 0.040 |
Why?
| | Adolescent | 4 | 2025 | 22281 | 0.040 |
Why?
| | Bone Marrow | 1 | 2022 | 304 | 0.040 |
Why?
| | Bioreactors | 1 | 2021 | 50 | 0.040 |
Why?
| | Microbial Viability | 1 | 2021 | 90 | 0.040 |
Why?
| | Spine | 1 | 2022 | 182 | 0.040 |
Why?
| | Water | 1 | 2023 | 469 | 0.040 |
Why?
| | Macrophages | 2 | 2020 | 1510 | 0.040 |
Why?
| | Chromatography, Thin Layer | 1 | 2020 | 27 | 0.040 |
Why?
| | THP-1 Cells | 1 | 2020 | 20 | 0.040 |
Why?
| | Cathelicidins | 1 | 2020 | 41 | 0.040 |
Why?
| | Glycolipids | 1 | 2020 | 52 | 0.040 |
Why?
| | Genetics, Population | 1 | 2021 | 214 | 0.040 |
Why?
| | Apolipoprotein E4 | 1 | 2019 | 41 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 682 | 0.040 |
Why?
| | Cell Line | 2 | 2015 | 2879 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 394 | 0.030 |
Why?
| | Age Factors | 1 | 2025 | 3313 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2021 | 519 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 732 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2016 | 2829 | 0.030 |
Why?
| | Child | 3 | 2025 | 22537 | 0.030 |
Why?
| | Disease Progression | 1 | 2025 | 2840 | 0.030 |
Why?
| | Membrane Proteins | 2 | 2014 | 1165 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2012 | 2929 | 0.030 |
Why?
| | Macrophages, Alveolar | 1 | 2020 | 368 | 0.030 |
Why?
| | Gambia | 1 | 2016 | 8 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2023 | 940 | 0.030 |
Why?
| | Hospitals | 1 | 2021 | 727 | 0.030 |
Why?
| | Regulon | 1 | 2016 | 34 | 0.030 |
Why?
| | Nitrogen Oxides | 1 | 2016 | 54 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2014 | 3539 | 0.030 |
Why?
| | Granuloma | 1 | 2016 | 96 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 427 | 0.030 |
Why?
| | India | 1 | 2016 | 218 | 0.030 |
Why?
| | Palatine Tonsil | 1 | 2016 | 55 | 0.030 |
Why?
| | Body Temperature Regulation | 1 | 2016 | 107 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2016 | 157 | 0.030 |
Why?
| | Replication Origin | 1 | 2015 | 21 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 189 | 0.030 |
Why?
| | Escherichia coli | 1 | 2020 | 852 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1258 | 0.030 |
Why?
| | Prevalence | 1 | 2022 | 2815 | 0.030 |
Why?
| | Latent Tuberculosis | 1 | 2015 | 71 | 0.030 |
Why?
| | Specimen Handling | 1 | 2016 | 185 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2014 | 35 | 0.030 |
Why?
| | Ataxins | 1 | 2014 | 5 | 0.030 |
Why?
| | Survival of Motor Neuron 2 Protein | 1 | 2014 | 5 | 0.030 |
Why?
| | Virus Integration | 1 | 2014 | 69 | 0.030 |
Why?
| | Survival of Motor Neuron 1 Protein | 1 | 2014 | 13 | 0.030 |
Why?
| | Lymphocyte Subsets | 1 | 2014 | 83 | 0.030 |
Why?
| | Multilocus Sequence Typing | 1 | 2014 | 17 | 0.030 |
Why?
| | Motor Neuron Disease | 1 | 2014 | 21 | 0.030 |
Why?
| | Extracellular Space | 1 | 2014 | 120 | 0.030 |
Why?
| | Saliva | 1 | 2016 | 249 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1533 | 0.030 |
Why?
| | Guinea Pigs | 1 | 2014 | 159 | 0.030 |
Why?
| | Cell Count | 1 | 2014 | 320 | 0.030 |
Why?
| | Accidental Falls | 1 | 2017 | 222 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 612 | 0.030 |
Why?
| | Burkitt Lymphoma | 1 | 2014 | 62 | 0.020 |
Why?
| | Autopsy | 1 | 2013 | 94 | 0.020 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 132 | 0.020 |
Why?
| | Muromegalovirus | 1 | 2013 | 23 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2014 | 322 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1054 | 0.020 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2013 | 29 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1312 | 0.020 |
Why?
| | United Kingdom | 1 | 2014 | 336 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2017 | 587 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2016 | 389 | 0.020 |
Why?
| | Receptors, Virus | 1 | 2013 | 96 | 0.020 |
Why?
| | Interferons | 1 | 2014 | 188 | 0.020 |
Why?
| | Interleukin-15 | 1 | 2013 | 97 | 0.020 |
Why?
| | Interleukin-12 | 1 | 2013 | 117 | 0.020 |
Why?
| | Gene Deletion | 1 | 2014 | 387 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 196 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 318 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 381 | 0.020 |
Why?
| | Hepatitis C | 1 | 2014 | 254 | 0.020 |
Why?
| | Drug Discovery | 1 | 2012 | 154 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 7970 | 0.020 |
Why?
| | Genetic Testing | 1 | 2013 | 478 | 0.020 |
Why?
| | NF-kappa B | 1 | 2014 | 661 | 0.020 |
Why?
| | Viral Proteins | 1 | 2012 | 355 | 0.020 |
Why?
| | Hypoxia | 1 | 2016 | 1199 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1187 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2010 | 2154 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1715 | 0.010 |
Why?
| | Phosphorylation | 1 | 2010 | 1732 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2013 | 3119 | 0.010 |
Why?
| | Vaccination | 1 | 2014 | 1422 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2013 | 4146 | 0.010 |
Why?
| | Biological Transport | 1 | 2006 | 412 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 6021 | 0.010 |
Why?
| | DNA Repair | 1 | 2006 | 255 | 0.010 |
Why?
| | Up-Regulation | 1 | 2006 | 851 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2006 | 525 | 0.010 |
Why?
| | Amino Acids | 1 | 2006 | 521 | 0.010 |
Why?
|
|
Strong's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|